Shares of Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) were up 5.1% during mid-day trading on Friday . The company traded as high as $3.69 and last traded at $3.69, with a volume of 96,374 shares trading hands. The stock had previously closed at $3.51.

Separately, Zacks Investment Research raised shares of Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 1st.

The firm’s market cap is $49.11 million. The stock has a 50-day moving average price of $3.86 and a 200-day moving average price of $4.38.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its quarterly earnings data on Thursday, May 12th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.16. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $3.24 million. On average, analysts expect that Imprimis Pharmaceuticals Inc. will post ($0.94) EPS for the current year.

Imprimis Pharmaceuticals, Inc (Imprimis) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns, markets and sells a portfolio of combination formulations in ophthalmology and urology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.